Airway administration of therapeutic antibody (tAb) confers higher protection than parenteral administration in a murine model of acute lung infection Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
Clinical and virusological effectiveness study of ultralow doses of antibodies to interferon-gamma in treatment of acute respiratory viral infections and influenza in children Source: Annual Congress 2009 - Diagnosis and treatment of viral respiratory infections in early childhood Year: 2009
Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma Source: Eur Respir J 2005; 26: Suppl. 49, 367s Year: 2005
Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Impact of the presence of serum neutralising antibodies on recruitment into experimental rhinovirus infection studies in asthmatic subjects Source: Annual Congress 2009 - Viruses and respiratory infections: prevalence and mechanisms of infection Year: 2009
Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
Durability of mepolizumab treatment response between doses Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Late Breaking Abstract - Anti-IL-4 and anti-IL-13 dual vaccination using Kinoid technology prevents development of allergic asthma in mice Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019
Effects of anti-IL-1α, anti-IL-1β, anti-IL-18 and anti-IL-1RI antibodies on combined smoke and virus-induced airway inflammation in mice Source: International Congress 2015 – New models for treating airway diseases Year: 2015
Immunogenicity assessment of intravenous administration of reslizumab in patients with asthma in phase 3 clinical studies Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021
Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019 Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011
New treatments for severe asthma Source: Eur Respir Mon 2011; 51: 268-281 Year: 2011
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Analysis of serum cytokine levels before and after isoprinosine treatment in children with acute viral respiratory infections Source: Annual Congress 2010 - From viral bronchiolitis to recurrent pneumonia in childhood: diagnosis, treatment and underlying factors Year: 2010
Efficacy of inductor of endogenous interferon's, cyclopheroni, in treatment of children with frequent acute respiratory infection (FARI) Source: Eur Respir J 2001; 18: Suppl. 33, 511s Year: 2001